MediWound Ltd.
MediWound (MDWD) reported that a DSMB review recommended continuing the Phase III VALUE study of EscharEx for venous leg ulcers without modifications, citing no safety concerns. The trial aims to enroll 216 patients, with completion expected by Q1 2027. MDWD's stock closed at $13.11 on September 11, 2026, and is up 2.21% in pre-market trading.
MediWound (MDWD) reported Q2 2026 progress in its EscharEx VALUE phase III trial and record U.S. sales for NexoBrid. The company said full-year revenue guidance of $24–$26 million was reaffirmed, while revenue fell year over year due to BARDA contract timing, with growth expected in H2 from government contracts and new programs.
MediWound Ltd. (MDWD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under it
Over the past 7 days, AlphAI's AI scored 1 news story mentioning MDWD (MediWound Ltd.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent MDWD coverage spans insider activity, financial news and technology.
In the last 30 days, MDWD insiders filed 5 SEC Form 4 transactions — 1 purchase ($7K) and 4 sales ($82K). The most active reporter was Hess Shmuel, COO & Chief Commercial Officer, with 3 filings.
Positive safety endorsement may reduce risk perception and support upside potential.
Reaffirmed 2026 revenue range with trial progress, but YoY revenue softness tied to BARDA timing suggests near-term visibility risk.
Earnings miss revenue expectations, but guidance unchanged; modest negative sentiment.
Insider open-market buying can modestly support sentiment, but the disclosure is not a fundamental catalyst by itself.
Insider buying is a modest bullish signal, but this small, single-tranche purchase is unlikely to drive a large fundamental repricing by itself.
AlphAI scores every news story that mentions MDWD with an AI model for sentiment and relevance, and aggregates insider trades from MediWound Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MediWound (MDWD) reported that a DSMB review recommended continuing the Phase III VALUE study of EscharEx for venous leg ulcers without modifications, citing no safety concerns. The trial aims to enroll 216 patients, with completion expected by Q1 2027. MDWD's stock closed at $13.11 on September 11, 2026, and is up 2.21% in pre-market trading.
1 min readMediWound (MDWD) reported Q2 2026 progress in its EscharEx VALUE phase III trial and record U.S. sales for NexoBrid. The company said full-year revenue guidance of $24–$26 million was reaffirmed, while revenue fell year over year due to BARDA contract timing, with growth expected in H2 from government contracts and new programs.
1 min readMediWound Ltd. (MDWD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under it
2 min readSHAMIR NACHUM purchased 5,825 shares of MediWound Ltd. (MDWD) at $14.00 on 2026-06-03.
1 min readSHAMIR NACHUM purchased 175 shares of MediWound Ltd. (MDWD) at $13.98 on 2026-06-03.
2 min readFox David Morton purchased 1,797 shares of MediWound Ltd. (MDWD) at $14.00 on 2026-06-01.
2 min readFox David Morton purchased 10 shares of MediWound Ltd. (MDWD) at $14.23 on 2026-06-01.
2 min readFox David Morton purchased 1,730 shares of MediWound Ltd. (MDWD) at $14.22 on 2026-06-01.
2 min readRubinstein Samuel purchased 150 shares of MediWound Ltd. (MDWD) at $14.33 on 2026-05-29.
1 min readMediWound (MDWD) delivered earnings and revenue surprises of +70.37% and -15.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min read
